RT Journal Article
T1 Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study.
A1 Montes, Maria Luisa
A1 Nelson, Mark
A1 Girard, Pierre-Marie
A1 Sasadeusz, Joe
A1 Horban, Andrzej
A1 Grinsztejn, Beatriz
A1 Zakharova, Natalia
A1 Rivero, Antonio
A1 Durant, Jacques
A1 Ortega-Gonzalez, Enrique
A1 Lathouwers, Erkki
A1 Janssen, Katrien
A1 Ouwerkerk-Mahadevan, Sivi
A1 Witek, James
A1 Gonzalez-Garcia, Juan
K1 Oligopeptides
K1 Polyethylene Glycols
K1 Recombinant Proteins
K1 Ribavirin
K1 Treatment Outcome
K1 Young Adult
AB INSIGHT (ClinicalTrials.gov NCT01513941) evaluated the efficacy, safety and pharmacokinetics of telaprevir-based therapy and specific antiretroviral agents in hepatitis C virus genotype 1 (HCV-1)/HIV-1-coinfected patients. Open-label, Phase IIIb, multicentre study of telaprevir with pegylated-IFN (Peg-IFN) α2a and ribavirin in treatment-naive or -experienced HCV-1/HIV-1-coinfected patients on stable HIV HAART comprising efavirenz, atazanavir/ritonavir, darunavir/ritonavir, raltegravir, etravirine or rilpivirine with two nucleos(t)ide analogues. Patients received 750 mg telaprevir (1125 mg, if on efavirenz) every 8 h plus 180 μg/week Peg-IFNα2a and 800 mg/day ribavirin for 12 weeks, followed by Peg-IFNα2a and ribavirin alone for 12 weeks (HCV treatment naive and relapsers without cirrhosis, with extended rapid virological response) or 36 weeks (all others). Overall, 162 patients (median age of 46 years, 78% male, 92% Caucasian and mean CD4 count of 687 cells/mm(3)) were treated; 13% had cirrhosis. One-hundred-and-thirty-two patients (81%) completed telaprevir; 14 (9%) discontinued due to an adverse event (AE). Sustained virological response (SVR) 12 rates ( In treatment-naive/-experienced HCV-1/HIV-1 patients there were significantly higher SVR rates with telaprevir-based therapy compared with pre-specified historical controls, and safety comparable to that in HCV-monoinfected patients.
PB Oxford University Press
YR 2015
FD 2015-09-08
LK http://hdl.handle.net/10668/10449
UL http://hdl.handle.net/10668/10449
LA en
NO Montes ML, Nelson M, Girard PM, Sasadeusz J, Horban A, Grinsztejn B, et al.  Telaprevir-based therapy in patients coinfected with chronic hepatitis C virus infection and HIV: INSIGHT study. J Antimicrob Chemother. 2016 Jan;71(1):244-50
DS RISalud
RD Apr 7, 2025